Theravance Biopharma Inc Analyst Price Targets - Benzinga

Theravance Biopharma Inc

TBPHNASDAQ

Trade with Public

Trade with Public

$17.04

0.0140.08%

Ult. Agg.: Sep 23, 5:58 PM

$17.04

0.0140.08%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Theravance Biopharma Inc Analyst Price Targets - Benzinga

Theravance Biopharma Inc Analyst Price Targets

Wall Street analyst price targets and consensus rating for Theravance Biopharma Inc (TBPH).

Price Target Range — 9 Quarters

Analyst Consensus — 6 Analysts

6Hold

Consensus RatingNeutral# Analysts6Avg. Consensus PT$15Upside to Avg. PT-13.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	BTIG	Julian Harrison	Suspends	Neutral	—
Jul 7, 2026	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$15→$17
Jun 29, 2026	Jones Trading	Debanjana Chatterjee	Downgrade	Buy→Hold	—
Jun 29, 2026	BTIG	Julian Harrison	Downgrade	Buy→Neutral	—
Apr 7, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Neutral	$14→$17
Mar 23, 2026	TD Cowen	Marc Frahm	PT Raise	Hold	$13→$15
Mar 20, 2026	BTIG	Julian Harrison	Maintained	Buy	$21
Mar 5, 2026	Oppenheimer	Trevor Allred	Downgrade	Outperform→Perform	—
Mar 4, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$27→$15
Mar 4, 2026	B. Riley Securities	Mayank Mamtani	Downgrade	Buy→Neutral	$28→$14
Mar 3, 2026	BTIG	Julian Harrison	PT Cut	Buy	$40→$21
Mar 2, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$20→$27
Feb 3, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Dec 3, 2025	Oppenheimer	Trevor Allred	Initiate	Outperform	$27
Nov 26, 2025	BTIG	Julian Harrison	PT Raise	Buy	$25→$40
Nov 11, 2025	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$15→$20
Sep 12, 2025	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$28
Jun 27, 2025	BTIG	Julian Harrison	PT Raise	Buy	$24→$25
Jun 17, 2025	Jones Trading	Debanjana Chatterjee	Initiate	Buy	$24
Feb 27, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Suspends Neutral Rating on Theravance Biopharma

BTIG suspends Neutral rating on Theravance Biopharma (NASDAQ:TBPH).

Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17

HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.

Benzinga Newsdesk

PRO
Jones Trading Downgrades Theravance Biopharma to Hold

Jones Trading analyst Debanjana Chatterjee downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Hold.

Benzinga Newsdesk

PRO
BTIG Downgrades Theravance Biopharma to Neutral

BTIG analyst Julian Harrison downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Neutral on Theravance Biopharma, Raises Price Target to $17

B. Riley Securities analyst Mayank Mamtani maintains Theravance Biopharma (NASDAQ:TBPH) with a Neutral and raises the price target from $14 to $17.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Theravance Biopharma, Raises Price Target to $15

TD Cowen analyst Marc Frahm maintains Theravance Biopharma (NASDAQ:TBPH) with a Hold and raises the price target from $13 to $15.

Benzinga Newsdesk